<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04168346</url>
  </required_header>
  <id_info>
    <org_study_id>HUS/333/2019</org_study_id>
    <nct_id>NCT04168346</nct_id>
  </id_info>
  <brief_title>Preoperative Intravenous Iron Therapy in Patients With Gastric Cancer</brief_title>
  <acronym>IRONSTOMACH</acronym>
  <official_title>Preoperative Intravenous Iron Therapy in Patients With Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this investigator initiated study is to study if preoperative
      intravenous iron is effective in reducing need for allogenic blood transfusion in patients
      with gastric cancer who will undergo a standardized gastrectomy including both total and
      subtotal gastrectomies. The hypothesis is that intravenous iron reduces the need for
      perioperative blood transfusions.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2019</start_date>
  <completion_date type="Anticipated">November 2026</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The need for blood transfusion</measure>
    <time_frame>Within 30 days from the day of the operation</time_frame>
    <description>Number of patients needing transfusions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative complications</measure>
    <time_frame>Within 30 days from operation</time_frame>
    <description>Postoperative complications measured using Comprehensive complication index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' quality of life (RAND)</measure>
    <time_frame>One and six months after the surgery</time_frame>
    <description>RAND questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' quality of life (15D)</measure>
    <time_frame>One and six months after the surgery</time_frame>
    <description>15D questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' quality of life (EQ-5D)</measure>
    <time_frame>One and six months after the surgery</time_frame>
    <description>EQ-5D questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' quality of life (FRAIL)</measure>
    <time_frame>One and six months after the surgery</time_frame>
    <description>FRAIL questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' quality of life (PRISMA-7)</measure>
    <time_frame>One and six months after the surgery</time_frame>
    <description>PRISMA-7 questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' quality of life (GSRS)</measure>
    <time_frame>One and six months after the surgery</time_frame>
    <description>GSRS questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' quality of life (IDQ)</measure>
    <time_frame>One and six months after the surgery</time_frame>
    <description>IDQ questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' haemoglobin and iron parameter levels</measure>
    <time_frame>At the time of hospital discharge (estimated on average 10 days after surgery)</time_frame>
    <description>Patients' haemoglobin and iron parameter levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' haemoglobin and iron parameter levels</measure>
    <time_frame>One month after the surgery</time_frame>
    <description>Patients' haemoglobin and iron parameter levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' haemoglobin and iron parameter levels</measure>
    <time_frame>Three months after the surgery</time_frame>
    <description>Patients' haemoglobin and iron parameter levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-admission</measure>
    <time_frame>30 days after discharge from hospital</time_frame>
    <description>Patient re-admission rates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90-day mortality</measure>
    <time_frame>Within 90 days from operation</time_frame>
    <description>90-day mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1, 3 and 5 years from operation</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>Within hospital stay, on average 7 - 14 days</time_frame>
    <description>Length of hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of IV iron after operation</measure>
    <time_frame>Within 3 months from operation</time_frame>
    <description>Number of doses and median dose of IV iron</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">202</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Anemia</condition>
  <condition>Surgery</condition>
  <condition>Iron Deficiency Anemia</condition>
  <condition>Surgery--Complications</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV-iron substitution: The intravenous iron formulation used in the study is ferric carboxymaltose and it will be administered two to four weeks before the surgery, aiming at four weeks. The dose of intravenous iron will be calculated according to the weight and haemoglobin level of the patients, however so that all the patients receive minimum 1000mg iv iron and the maximum dose is 20 mg/kg per day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo is NaCl 0.9% solution, which is administrated in the same way as the study drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferric carboxymaltose</intervention_name>
    <description>Ferric carboxymaltose iv infusion</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>NaCl 0.9% infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Patients with gastric cancer who will undergo a gastrectomy

        Exclusion Criteria:

          -  Patients under 18 years old

          -  Patients not in full understanding

          -  Hemoglobin levels &gt; 155 g/l for women and &gt;167 g/l for men (upper reference limits for
             the laboratory of Helsinki University Hospital district) preoperatively.

          -  Transferrin saturation level &gt;50%

          -  Emergency gastrectomy

          -  Palliative gastrectomy

          -  Acute bacterial infection

          -  Known hypersensitivity to the active substance, to ferric carboxymaltose or any of its
             excipients, or to other parental iron products

          -  Clinical evidence of iron overload or disturbances in the utilisation of iron

          -  Patients &lt;35 kg

          -  Dialysis therapy for chronic renal failure

          -  Hemochromatosis

          -  Polycythemia vera

          -  Pregnancy

          -  Patients in need of direct blood transfusion ( Criteria for this are hemoglobin &lt; 80
             g/l or &lt; 90 g/l if the patient is symptomatic or has a history of heart disease)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arto Kokkola, MD</last_name>
    <role>Study Director</role>
    <affiliation>Helsinki University Central Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arto Kokkola, MD</last_name>
    <phone>+358-9-4711</phone>
    <email>arto.kokkola@hus.fi</email>
  </overall_contact>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 12, 2019</study_first_submitted>
  <study_first_submitted_qc>November 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2019</study_first_posted>
  <last_update_submitted>November 16, 2019</last_update_submitted>
  <last_update_submitted_qc>November 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Ville Sallinen</investigator_full_name>
    <investigator_title>MD, Phd, Adj. Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

